Oral GLP-1 Drug Development Trends: Small-Molecule Innovation and Industry Competition

In recent years, GLP-1 receptor agonists (GLP-1 RAs) have become one of the most closely watched therapeutic areas in the global metabolic disease landscape. Among these, oral GLP-1 drug development trends have emerged as a key focus, as the field shifts from injectable therapies to innovative oral treatments.

With breakthroughs in oral small-molecule GLP-1 drugs, the global metabolic treatment market is entering a new phase of competition. These advances are reshaping market structure and long-term industry direction, particularly as oral therapies gain increasing attention across the pharmaceutical sector.

From the perspective of oral GLP-1 drug development trends, these developments signal a critical turning point for pharmaceutical innovation and global drug supply.

Global pharmaceutical distributor DengYueMed analyzes key shifts in oral GLP-1 drug development trends from three dimensions: R&D progress, competitive dynamics, and evolving industry directions.

Oral GLP-1 Drug Development Trends Enter a Rapid Growth Phase

Currently, there are 84 oral small-molecule GLP-1 drug candidates in development worldwide, with 52 already in clinical stages.

These numbers highlight the accelerating investment by pharmaceutical companies in the oral GLP-1 sector as they seek to capture opportunities in the rapidly expanding obesity and metabolic disease markets.

For many years, the GLP-1 drug market was dominated by injectable therapies such as Semaglutide and Tirzepatide. However, injectable medications still face certain limitations in terms of convenience, patient adherence, and large-scale supply.

As a result, oral GLP-1 drugs are widely viewed as the next major breakthrough for expanding the market.

Compared with injectable formulations, oral small-molecule drugs offer several potential advantages: 🔽

• Greater convenience for patients
• Easier scalability in large-scale manufacturing
• More flexibility in cost control
• Higher potential for broader market penetration

These dynamics continue to define oral GLP-1 drug development trends as global pharmaceutical companies accelerate investment in this sector.

Orforglipron: A Breakthrough in Oral GLP-1 Small-Molecule Drug Development

On April 1, 2026, Eli Lilly and Company announced that its oral small-molecule GLP-1 receptor agonist Orforglipron had received approval from the U.S. Food and Drug Administration for the treatment of adults with obesity or overweight.

✨ This drug became the world’s first approved non-peptide oral small-molecule GLP-1 receptor agonist, marking a major milestone in the transition of the GLP-1 therapeutic field toward small-molecule innovation.

Orforglipron offers several notable characteristics:

• Once-daily oral administration
• No injections required
• Flexible dosing schedule
• No strict restrictions regarding food or water intake

These features provide significant advantages in patient adherence and convenience.

Orforglipron was originally discovered by Chugai Pharmaceutical. In 2018, Eli Lilly and Company acquired the global development rights and subsequently advanced the drug through international clinical trials.

Currently, Lilly has submitted marketing applications for Orforglipron for weight loss or diabetes treatment in more than 40 countries. This milestone further highlights the importance of oral GLP-1 drug development trends in shaping the next phase of GLP-1 innovation.

Oral Semaglutide vs Small-Molecule GLP-1: Key Differences in Development and Manufacturing

At the same time, another GLP-1 giant, Novo Nordisk, is accelerating the commercialization of its oral weight-loss therapies.

On December 22, 2025, the U.S. Food and Drug Administration approved an oral formulation of Semaglutide for weight management, allowing it to enter the obesity treatment market. Subsequently, on January 5, 2026, the product was officially launched in the United States.

✨ Wegovy, based on semaglutide, is already one of the most influential GLP-1 drugs globally, supported by strong clinical evidence and widespread brand recognition. The introduction of an oral formulation further expands its application and reinforces Novo Nordisk’s position in the obesity treatment market.

However, compared with small-molecule GLP-1 drugs such as Orforglipron, oral semaglutide remains a peptide-based therapy. This distinction leads to key differences in development and manufacturing: 🔽

• Peptide-based GLP-1 drugs require complex synthesis and formulation processes
• Small-molecule GLP-1 drugs are generally easier to manufacture at scale
• Oral bioavailability and stability present different technical challenges

These differences highlight the contrasting development paths between peptide-based and small-molecule GLP-1 therapies, which continue to shape industry competition.

Many industry analysts believe that small-molecule GLP-1 drugs may offer long-term advantages in manufacturing scalability and production costs—an important point that continues to shape oral GLP-1 drug development trends.

Oral GLP-1 Drugs in China: Market Entry and Development Outlook

Compared with Europe and the United States, the oral GLP-1 weight-loss drug market in China is still in its early development stage.

So far, no oral GLP-1 weight-loss drug has been approved in China. However, multinational pharmaceutical companies have already begun building localized production and supply networks in anticipation of future demand.

On March 11, 2026, Eli Lilly and Company announced plans to invest approximately $3 billion over the next decade to expand its supply chain capacity in China.

The investment will focus on: 🔽

• Building oral solid-dose manufacturing capacity
• Establishing localized supply systems
• Supporting the production and supply of Orforglipron

This project represents one of the largest global manufacturing expansion initiatives in Lilly’s history.

At the same time, Orforglipron has submitted a marketing application to the National Medical Products Administration for the treatment of type 2 diabetes and obesity in China. DengYueMed will continue monitoring and updating developments related to the regulatory review process.

With rising obesity rates and a growing population of metabolic disease patients, China is widely expected to become one of the most important future growth markets for GLP-1 therapies. This perspective is frequently highlighted in forward-looking GLP-1 weight loss drug market analysis.

The Era of Small-Molecule GLP-1 Drugs Is Emerging

The approval of Orforglipron represents more than the launch of a new drug—it reflects a major shift in oral GLP-1 drug development trends toward small-molecule innovation.

Over the past decade, GLP-1 therapies have largely relied on peptide-based injectable drugs. However, the emergence of oral small-molecule therapies could reshape the competitive logic of the entire industry.

This transformation may influence the market in three major ways.

1. Changes in Manufacturing Models

Small-molecule drugs are typically produced through chemical synthesis, which is more suitable for large-scale industrial manufacturing.

In contrast, peptide-based drugs involve more complex production processes and higher technical requirements.

2. Improved Supply Capacity

As global demand for weight-loss therapies continues to grow rapidly, manufacturing capacity has become a critical competitive factor.

Small-molecule GLP-1 drugs may offer greater flexibility in scaling production.

3. Higher Market Penetration

Oral medications are generally easier for patients to accept and more suitable for long-term treatment.

This means that GLP-1 therapies may gradually expand from specialist treatment settings to broader chronic disease management markets.

These structural shifts continue to shape the conclusions of many GLP-1 weight loss drug market analysis discussions across the pharmaceutical industry.

Future GLP-1 Market Trends: Competition and Innovation

At present, the GLP-1 weight-loss drug market is still largely dominated by Eli Lilly and Company and Novo Nordisk.

However, breakthroughs in oral small-molecule drugs may significantly reshape the competitive landscape.

In the coming years, several trends are likely to emerge:

• Rapid growth in the number of oral GLP-1 drugs
• Small-molecule GLP-1 therapies becoming a major R&D focus
• Manufacturing capacity becoming a key competitive factor
• Continued entry of emerging biotechnology companies into the sector

At the same time, dual-target GLP-1 drugs, GLP-1/GIP co-agonists, and oral multi-target metabolic therapies are also advancing rapidly.

These innovative therapies are expected to further drive the next growth cycle of the global obesity drug market, a conclusion consistently highlighted in GLP-1 weight loss drug market analysis.

Conclusion

With continuous breakthroughs in oral GLP-1 therapies, oral GLP-1 drug development trends are driving a new growth cycle in the global metabolic disease treatment landscape.

From injectable therapies to oral small-molecule drugs, the evolution of technology is reshaping industry supply chains, manufacturing models, and competitive dynamics. 🚀

Over the next several years, as more innovative therapies enter clinical development and commercialization, the GLP-1 field is expected to maintain rapid growth while expanding into broader metabolic disease management.

As a global pharmaceutical distributor, DengYueMed focuses on innovative drug supply and cross-border medical services, connecting international pharmaceutical resources and facilitating global access to advanced therapies.

FAQ about Oral GLP-1 Drug Development Trends